0001062993-24-005756.txt : 20240306
0001062993-24-005756.hdr.sgml : 20240306
20240306193834
ACCESSION NUMBER: 0001062993-24-005756
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240125
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOBULSKY SUSAN
CENTRAL INDEX KEY: 0001820885
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 24727752
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
3
1
form3.xml
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
X0206
3
2024-01-25
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001820885
BOBULSKY SUSAN
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1165 EASTLAKE AVENUE EAST
SEATTLE
WA
98109
0
1
0
0
Chief Commercial Officer, MRD
Common Stock
128302
D
Stock Option (Right to Buy)
1.98
2024-10-13
Common Stock
5000
D
Stock Option (Right to Buy)
6.27
2027-04-25
Common Stock
20000
D
Stock Option (Right to Buy)
6.55
2028-04-24
Common Stock
28750
D
Stock Option (Right to Buy)
28.32
2030-02-27
Common Stock
13474
D
Stock Option (Right to Buy)
39.50
2030-08-13
Common Stock
20000
D
Stock Option (Right to Buy)
43.68
2031-03-04
Common Stock
22894
D
Stock Option (Right to Buy)
12.14
2032-03-04
Common Stock
102965
D
Stock Option (Right to Buy)
8.46
2033-03-06
Common Stock
88689
D
The options are fully exercisable.
The options will vest with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options will vest with respect to 1/4 of such shares on August 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options will vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options will vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options will vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Susan Bobulsky by Stacy L. Taylor, Attorney-in-Fact
2024-03-06